Cargando…

Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes

Carotid bodies (CBs) are peripheral chemoreceptors that sense changes in blood O(2), CO(2), and pH levels. Apart from ventilatory control, these organs are deeply involved in the homeostatic regulation of carbohydrates and lipid metabolism and inflammation. It has been described that CB dysfunction...

Descripción completa

Detalles Bibliográficos
Autores principales: Sacramento, Joana F., Andrzejewski, Kryspin, Melo, Bernardete F., Ribeiro, Maria J., Obeso, Ana, Conde, Silvia V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432672/
https://www.ncbi.nlm.nih.gov/pubmed/32756352
http://dx.doi.org/10.3390/ijms21155545
_version_ 1783571848801288192
author Sacramento, Joana F.
Andrzejewski, Kryspin
Melo, Bernardete F.
Ribeiro, Maria J.
Obeso, Ana
Conde, Silvia V.
author_facet Sacramento, Joana F.
Andrzejewski, Kryspin
Melo, Bernardete F.
Ribeiro, Maria J.
Obeso, Ana
Conde, Silvia V.
author_sort Sacramento, Joana F.
collection PubMed
description Carotid bodies (CBs) are peripheral chemoreceptors that sense changes in blood O(2), CO(2), and pH levels. Apart from ventilatory control, these organs are deeply involved in the homeostatic regulation of carbohydrates and lipid metabolism and inflammation. It has been described that CB dysfunction is involved in the genesis of metabolic diseases and that CB overactivation is present in animal models of metabolic disease and in prediabetes patients. Additionally, resection of the CB-sensitive nerve, the carotid sinus nerve (CSN), or CB ablation in animals prevents and reverses diet-induced insulin resistance and glucose intolerance as well as sympathoadrenal overactivity, meaning that the beneficial effects of decreasing CB activity on glucose homeostasis are modulated by target-related efferent sympathetic nerves, through a reflex initiated in the CBs. In agreement with our pre-clinical data, hyperbaric oxygen therapy, which reduces CB activity, improves glucose homeostasis in type 2 diabetes patients. Insulin, leptin, and pro-inflammatory cytokines activate the CB. In this manuscript, we review in a concise manner the putative pathways linking CB chemoreceptor deregulation with the pathogenesis of metabolic diseases and discuss and present new data that highlight the roles of hyperinsulinemia, hyperleptinemia, and chronic inflammation as major factors contributing to CB dysfunction in metabolic disorders.
format Online
Article
Text
id pubmed-7432672
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74326722020-08-27 Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes Sacramento, Joana F. Andrzejewski, Kryspin Melo, Bernardete F. Ribeiro, Maria J. Obeso, Ana Conde, Silvia V. Int J Mol Sci Review Carotid bodies (CBs) are peripheral chemoreceptors that sense changes in blood O(2), CO(2), and pH levels. Apart from ventilatory control, these organs are deeply involved in the homeostatic regulation of carbohydrates and lipid metabolism and inflammation. It has been described that CB dysfunction is involved in the genesis of metabolic diseases and that CB overactivation is present in animal models of metabolic disease and in prediabetes patients. Additionally, resection of the CB-sensitive nerve, the carotid sinus nerve (CSN), or CB ablation in animals prevents and reverses diet-induced insulin resistance and glucose intolerance as well as sympathoadrenal overactivity, meaning that the beneficial effects of decreasing CB activity on glucose homeostasis are modulated by target-related efferent sympathetic nerves, through a reflex initiated in the CBs. In agreement with our pre-clinical data, hyperbaric oxygen therapy, which reduces CB activity, improves glucose homeostasis in type 2 diabetes patients. Insulin, leptin, and pro-inflammatory cytokines activate the CB. In this manuscript, we review in a concise manner the putative pathways linking CB chemoreceptor deregulation with the pathogenesis of metabolic diseases and discuss and present new data that highlight the roles of hyperinsulinemia, hyperleptinemia, and chronic inflammation as major factors contributing to CB dysfunction in metabolic disorders. MDPI 2020-08-03 /pmc/articles/PMC7432672/ /pubmed/32756352 http://dx.doi.org/10.3390/ijms21155545 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sacramento, Joana F.
Andrzejewski, Kryspin
Melo, Bernardete F.
Ribeiro, Maria J.
Obeso, Ana
Conde, Silvia V.
Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes
title Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes
title_full Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes
title_fullStr Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes
title_full_unstemmed Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes
title_short Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes
title_sort exploring the mediators that promote carotid body dysfunction in type 2 diabetes and obesity related syndromes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432672/
https://www.ncbi.nlm.nih.gov/pubmed/32756352
http://dx.doi.org/10.3390/ijms21155545
work_keys_str_mv AT sacramentojoanaf exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes
AT andrzejewskikryspin exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes
AT melobernardetef exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes
AT ribeiromariaj exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes
AT obesoana exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes
AT condesilviav exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes